Articles By Jack Cush, MD
FDA Approves Taltz for Psoriasis
Tuesday the FDA approved the IL-17 inhibitor, Taltz (ixekizumab) for adults with moderate to severe plaque psoriasis. (Citation source http://buff.ly/1py10wd)
Read Article
Statin-Induced Autoimmune Myopathy
The CDC estimates nearly 71% of adults with cardiovascular disease and 54% of adults with hypercholesterolemia use a cholesterol-lowering
Read Article
Hemochromatosis Reviewed
Powell et al have published in Lancet a review of hemochromatosis; its genetics, pathogenesis, clinical manifestations and management.
Read Article
MMWR Update on Zika Virus: 116 US Cases Related to Travel
The Centers for Disease Control and Prevention (CDC) reported that in the last year (January 2015 to February 2016), they have identified and confirmed 116 cases of the Zika virus among US residents, with nearly all having traveled to endemic regions.
Read Article
Differences in Diuretic-Induced Gout
Diuretics are frequently implicated causes of hyperuricemia and gout. And there are gout variants wherein age, renal dysfunction and diuretic use may give rise to gouty attack in the hands of women with nodal osteoarthritis.
Read Article
The Week in Review 18 March 2016
See the highlights from the past week that appeared on RheumNow.com, and watch Dr. Jack Cush as he reviews each of them.
Read Article
Bisphosphonate Use Falls Following FDA Warnings
In the current issue of JBMR, Kim and colleagues from Brigham and Women's Hospital in Boston assessed US claims data and studied the impact of three FDA drug safety warnings regarding the use of bisphosphonates.
Read Article
Acetaminophen: No Effect in Osteoarthritis Pain or Function
A network analysis of multiple therapies used in osteoarthritis found that acetaminophen (paracetamol) does not meet the minimum standard of clinical effectiveness in reducing pain or improving physical function in patients with knee and hip osteoarthritis.
Read Article
January/February 2016 Top Social Media News
In February 2016, RheumNow published 82 tweets about impactful news, research and teaching points that impact the rheumatology community. These feeds had a reach (impressions) of 80,800 with, 76 mentions, and over 2700 visits to learn on RheumNow.com.
Read Article
Sclerostin Inhibition May Worsen Rheumatoid Arthritis
Sclerostin, an inhibitor of the Wnt/β-catenin pathway, negatively regulates osteoblast differentiation and has anti-anabolic effects on bone formation. Thus, inhibition of sclerostin is currently being studied as therapy for postmenopausal osteoporosis.
Read Article
